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Abstract

VITAMIN B6 METABOLISM AND REGULATION OF PYRIDOXAL KINASE

By Amit K. Gandhi, Ph.D.

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: Martin K. Safo, Ph.D
Assistant Professor, Department of Medicinal Chemistry

Pyridoxal 5'-phosphate (PLP) is the cofactor for over 140 vitamin B6 (PLP)dependent enzymes that are involved in various metabolic and biosynthetic pathways.
Pyridoxal kinase (PL kinase) and pyridoxine 5’-phosphate oxidase (PNP oxidase) are the
two key enzymes that metabolize nutritional forms of vitamin B6, including pyridoxal
(PL), pyridoxine (PN), and pyridoxamine (PM) to the active cofactor form, PLP.
Disruption of the PLP metabolic pathway due to mutations in PNP oxidase or PL kinase
result in PLP deficiency, which is implicated in several neurological pathologies. Several
ingested compounds are also known to result in PLP deficiency with concomitant
neurotoxic effects. How these mutations and compounds affect B6 metabolism is not
clearly understood. On the other hand, an emerging health problem is the intake of too
xiv

much vitamin B6 as high doses of the reactive PLP in the cell exhibits toxic effects,
including sensory and motor neuropathies. The overall aim of this research is to understand
the catalytic function of PL kinase and the regulatory pathway of PLP metabolism.
Using site-directed mutagenesis (Asp235Asn, Asp235Ala), kinetic and structural
studies, we have shown that Asp235 may play a catalytic role in PL kinase
phosphorylation activity. We also show that human PL kinase binds its substrates, PL and
MgATP synergistically, and that the enzyme requires Na+ (or K+) and Mg2+ for its activity.
Using kinetic study, we show severe induced MgATP substrate inhibition of PL kinase in
the presence of its product, PLP, and we postulate this to be due to the formation of a nonproductive ternary complex (Enzyme•PLP•MgATP). Consistently, our crystal structure of
human PL kinase (2.1 Å) co-crystallized with MgATP and PLP showed both MgATP and
PLP trapped at the active site. Our hypothesis is that this abortive ternary complex might
be a physiological process, and that PL kinase uses this mechanism to self-regulate its
activity.
Our inhibition studies show theophylline, a bronchodilator as a mixed competitive
inhibitor of human PL kinase with Ki of 71 µM. Our structural study (2.1 Å) shows
theophylline bound at the substrate, PL binding site of human PL kinase. We also
identified several potential PL kinase inhibitors from the DrugBank Chemical Compound
database. Some of these compounds, including enprofylline, theobromine, caffeine, and
lamotrigine, which incidentally exhibit similar neurotoxic effects as theophylline, show
significant inhibitory effect on human PL kinase. Further studies are also planned to
investigate

the

effect

of

these

drugs
xv

on

vitamin

B6

metabolism

in

vivo.

CHAPTER 1
General Introduction

1.1 Pathways of vitamin B6 metabolism: There are six B6 vitamers, including the
primary forms pyridoxal (PL), pyridoxine (PN), and pyridoxamine (PM), and their
phosphate derivatives PLP, PNP, and PMP (Figure 1). PLP, and to a lesser extent PMP,
are the active cofactor forms that are used by various vitamin B6 (PLP)- dependent
enzymes for their activities.1 Mammals cannot synthesize PLP de novo and use the dietary
PN, PL and PM. Figure 2 shows the metabolic cycle of B6 in mammals. This pathway
involves PL kinase that phosphorylates PL, PN, and PM to PLP, PNP and PMP,
respectively (rxn. 1, Figure 2). PNP and PMP are then converted to PLP by PNP oxidase
(rxn. 2, Figure 2).2, 3
CH2OH
HO

H3C

CH2OH

N

CH2NH2
HO

CH2OH

H3C

Pyridoxine (PN)

N
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Figure 1: Structures of the six B6 vitamers

1

CH2OPO3H2

In bacteria, plants and fungi this cycle exists in addition to a de novo biosynthetic
pathway from common cellular metabolites. Another pathway for synthesizing PLP is the
salvage pathway during protein degradation, where PMP, PNP and PLP are
dephosphorylated by phosphatases to PM, PN and PL, followed by their conversion to PLP
by the oxidase and/or kinase as shown in Figure 2. Several studies have shown that several
phosphatases can perform this task and they have high turnover numbers.4,

5, 6

The kcat

values of phosphatases are 30-fold higher than that of PL kinase and even several-fold
greater than that of PNP oxidase.6 The cellular content of PLP is thus dependent on PL
kinase, PNP oxidase and phosphatases. PLP synthesized by PL kinase or PNP oxidase is
used by several apo-B6 enzymes as a cofactor to form the catalytically competent holoenzymes (rxn. 3, Figure 2).4,

5, 6

Both PL kinase and PNP oxidase are therefore key to

supplying enough PLP to meet the requirement of the cell.

PN, PM
salvage pathway

amino
acids

ATP

ATP

1 PL kinase

1 PL kinase
ADP + Pi

ADP + Pi

PNP, PMP
de novo synthesis

PL

holo B6 Enzyme

2
PNP oxidase

PLP

3

apo B6 Enzyme

Figure 2: Scheme for the salvage pathway of vitamin B6 metabolism

2

1.2 Structure and function of Pyridoxal Kinase: PL kinase catalyzes the addition
of γ-phosphate of ATP to the 5’ alcohol of PN, PM and PL and forms PNP, PMP and PLP,
respectively (Figure 3).4

Figure 3: PL kinase catalyzed reaction

Currently the protein data bank lists amino acid sequences for over 100 close
homologs of PL kinases from both prokaryotes and eukaryotes. The sequence identity
ranges from 24-90 % to the human enzyme. Detailed sequence analysis of these PL kinase
enzymes has been reported.7, 8 A few of these enzymes have been studied to explore the
substrate-binding site using inhibitors, chemical modification methods, spectroscopy and
X-ray crystallography.9-13 PL kinases have been purified from bacterial, plant and
mammalian sources and evidence suggests that most eukaryote organisms contain a single
PL kinase, coded by a pdxK gene. In contrast, prokaryotes contain two isoform PL kinases,
encoded by pdxK and pdxY genes. The enzyme coded by the pdxY gene is not catalytically
active, and subsequent mention of PL kinase is referred to the enzyme coded by the pdxK
gene.14, 15

3

The crystal structures of E. coli PL kinase (ePL kinase) and sheep PL kinase (shPL
kinase) have been elucidated, which show the enzyme to be a homodimer with one active
site per monomer (Figure 4).7-8,

11-12

All these kinases are members of the ribokinase

superfamily as their crystal structures show the same typical ribokinase superfamily central
core structure of β-sheets surrounded by α-helices, as well as conserved ATP and substrate
binding site geometries. Unlike the prokaryotes, the eukaryote PL kinases are known to
exhibit a relatively broad substrate specificity tolerating modifications at the 4'-position of
vitamin B6. Structural studies of ePL kinase, and shPL kinase suggest that the different
specificities may be due to differences in the active site structures.7-8, 11-12

Figure 4: Homodimeric structure of ePL kinase with bound PL (grey) and ATP ( blue).

1.3 Catalytic mechanism of Pyridoxal kinase: The phosphorylation mechanism
has been elucidated for ePL kinase and shPL kinase, and follows a random sequential
substrate addition. The enzyme requires the metal ion tandem, such as Mg2+ and K+ for
activity. Asp235 is a conserved residue at the active site of PL Kinase. This residue is also
4

conserved in the ribokinase superfamily, and there is speculation that this residue serves as
a base to deprotonate the substrate, PL prior to phosphorylation. 7-9, 16
1.4 Pyridoxine 5’-phosphate oxidase: PNP oxidase catalyzes the terminal step in
the synthesis of PLP by oxidizing the 4’-hydroxyl group of PNP or the 4’-amino group of
PMP to an aldehyde, forming PLP with the transfer of 2 electrons to a tightly bound FMN,
forming FMNH2 (Figure 5). FMN is regenerated by transfer of the two electrons to oxygen
forming hydrogen peroxide which is decomposed to water and oxygen by enzyme catalase.
4, 17-19

CHO

CH2OH
HO

H3C

OPO32- PNP Oxidase
N
PNP

FMN

H2O2

HO

FMNH2 H3C

OPO32N
PLP

O2

Figure 5: Reaction catalyzed by PNP oxidase

Structure of E. coli PNP oxidase (ePNP oxidase) in complex with FMN has been
reported. This was the first enzyme in both the B6 biosynthetic and salvage pathways for
which a crystal structure was determined (Figure 6).17 Later, ternary crystal structures of
the human and E. coli PNP oxidase complexes with PLP (or PNP) and FMN in various
active site conformations were also determined to gain insight into substrate binding and
catalytic mechanism. Both human and E. coli enzymes have similar dimer folds, with each
monomer containing FMN.17-19
5

Figure 6: Homodimeric structure of ePNP oxidase with bound FMN (red) and PLP (brown).

1.5 Vitamin B6 requiring enzymes: PLP is used by several apo-B6 enzymes to
form the catalytically active holo-enzymes. These enzymes are important in metabolic
pathways

involving

carbohydrates,

sphingolipids,

amino

acids,

heme,

and

neurotransmitters.20-24 The functional diversity of B6 enzymes is illustrated by the fact that
145

distinct

enzymatic

activities

noted

by

the

Enzyme

Commission

(http://www.chem.qmul.ac.uk/iubmb/enzyme/) are PLP dependent, corresponding to ~4%
of all classified activities. These enzymes are oxidoreductases, transferases, hydrolases,
lyases and isomerases. The functions of many others are unknown.24 The three
dimensional structures of over 30 different PLP-dependent enzymes have been determined.
In addition, the catalytic function, folding mechanism, as well as the substrate and reaction
specificity of several of these enzymes have also been elucidated.20, 24

6

The PLP-dependent enzymes have been classified into at least 5 different fold-types
based on amino acid sequence comparisons, predicted secondary structure elements and
available three-dimensional structural information. Fold-type I is the largest family, and is
further divided into at least 2 subclasses based on differences in conformation of the Nterminal part of the subunits. Some named examples of fold-type I enzymes are serine
hydroxymethyltransferase (SHMT), glutamate decarboxylase (GAD), and aspartate
aminotransferase (AAT).

Examples of fold-type II are D-serine dehydratase and

tryptophan synthase; examples of fold-type III are alanine racemase and eukaryotic
ornithine decarboxylase; examples of fold-type IV are D-aminoacid aminotransferase and
branched chain amino acid transferase; and an example of fold-type V is glycogen
phosphorylase, the most abundant enzyme requiring PLP. PLP binds to these enzymes as
an aldimine (Schiff-base) to an ε-amino group of lysine.26, 27
There is evidence to suggest that PLP synthesized by PL kinase or PNP oxidase is
channeled to PLP-dependent enzymes.28,

29

The Churchich group using fluorescence

spectroscopy, affinity chromatography and a trapping agent (alkaline phosphatases)
showed that PL kinase forms a complex with AAT (Kd of 3 µM), and that the trapping
agent did not inhibit the transfer of PLP to the apo-B6 enzyme.28 A more recent study using
fluorescence polarization and surface plasmon resonance (SPR) analyses showed that PL
kinase can bind to AAT and GAD with dissociation constants of 4.9 µM and 2.7 µM,
respectively.29 Channeling would avoid PLP being destroyed by phosphatases or
potentially interacting with other proteins because of the reactive PLP aldehyde moiety.
This brings up an intriguing question as to how PL kinase and PNP oxidase, two
7

structurally different enzymes are able to recognize and interact with the over 140 B6dependent enzymes that differ widely in their structural fold.
1.6 Vitamin B6 enzymes, neurotransmitters and brain function: Figure 7 shows
a partial list of neurotransmitters, whose synthesis requires PLP-dependent enzymes.
Pathway A: GABA is the major inhibitory neurotransmitter in the mammalian CNS, and
low levels are implicated with symptoms associated with epilepsy, convulsions,
Parkinson’s, Alzheimer’s and Huntington’s.30-34 Pathways B and C: Dopamine,
norepinephrine, epinephrine and serotonin have been implicated in Parkinson’s disease and
attention deficit hyperactivity disorder (ADHD).35 Pathway D: D-serine serves as a coagonist of the N-methyl D-aspartate receptor in mammalian brains, and its behavior is
believed to be related to neurological disorders such as schizophrenia, Alzheimer's disease
and amyotrophic lateral sclerosis.36 Pathway E: Histamine, in addition to its role in
hypersensitivity reactions, also plays an important role in memory.37, 38
PLP, PNP or PMP do not easily cross the blood–brain barrier, therefore they must
be synthesized within brain tissues from the primary B6 vitamers. Disruption of the salvage
pathway could therefore lead to a decrease of PLP in the brain.6 Because many B6 enzymes
in the brain compete for PLP, even a modest decrease in PLP availability could result in
low levels of neurotransmitters with dire consequences on brain function. In a study by the
Stover group, restriction of PN in MCF-7 cells led to a significant drop in cytosolic SHMT
activity compared to mitochondrial SHMT.39 This shows that PLP is not distributed
equally among competing apo-B6 enzymes. How this co-enzyme is made available to many
apo-B6 enzymes is therefore of profound interest.
8

A. Leucine or Valine

B. Tyrosine

C. Tryptophan
D. L-Serine
E. Histidine

BCAT

Tyr
hydroxylase
DOPA

Glutamate
AAAD

Dopamine

Trp
hydroxylase
L-5-Hydroxytryptophan
Serine
Racemase
HDC

GAD
Dopamine
hydroxylase

AAAD

GABA

Norepinephrine
phenylethanolamineN-methyltransferase
Epinephrine
Serotonin

D-Serine
Histamine

Figure 7: Synthesis of neurotransmitters by B6 enzymes (colored red)

1.7 PLP and Vitamin B6 toxicity: There are many potential toxic compounds in
the cell, e.g. aldehydes, radicals, etc, that are part of metabolism. Cells have developed
mechanisms to remove or keep their concentrations low. Aldehydes react with
nucleophiles, especially amines, to form aldimines. Generally, aldehydes do not cause
problems until raised to higher levels by an environmental insult or a genetic defect, e.g.,
advanced glycation end products implicated in diabetes due to sugar aldehydes reacting
irreversibly with proteins.40 PLP has been used often as a general Lys labeling reagent for
proteins because of the high reactivity of the 4'-aldehyde. It is known that excessive doses
of vitamin B6 (> 200 mg/day) cause several health problems. The current recommended
dietary allowance (RDA) for vitamin B6 is 2 mg/day in the United States. Vitamin B6
toxicity is known to damage sensory nerves, leading to numbness in the hands and feet, as
well as difficulty in walking.41-50 The sensory neuropathy is usually reversible when
supplementation is stopped.48 However, some patients are known to develop acute,
9

profound and permanent sensory neuropathy, and in some instances motor neuropathy and
damage of the central nervous system.46, 49, 50 High doses of B6 are also found to induce
convulsions in rats, which was suggested to be caused by formation of an aldimine
between PLP and a lysine residue located in an extracellular loop of the GABA receptor.41
In another study, PLP was observed to inhibit phenol sulfotransferase, a detoxification
enzyme.47 This begs the question as to how the cell regulates PLP to prevent toxic effects?
1.8 MgATP substrate inhibition of PL kinase in the presence of PLP:
Accumulation of PLP in the cell as a free molecule must be kept low. PLP is a very
reactive compound that forms aldimines with amino acids and Lys residues on proteins,
and has been shown to result in toxic effects in humans and animal models.41-50
Dephosphorylation of PLP is a well-known mechanism the cell uses to maintain low levels
of free PLP.6 Another proposed mechanism, which is presently not well understood, is
regulation of PLP synthesis by PL kinase and/or PNP oxidase. In our previously published
study with E. coli PL kinase, severe substrate inhibition of enzyme by MgATP in the
presence of PNP or PLP was observed, suggesting possible feedback regulatory
mechanism of PL kinase activity.8
1.9 Vitamin B6 deficiency: A 2 mg/day RDA for Vitamin B6 has been assumed to
be adequate to maintain physiological plasma levels of B6 at 20 nmol/L, however, a recent
study has suggested that the RDA may be too low for some sections of the population due
to the following: (i) inborn errors in PL kinase and/or PNP oxidase affecting the pathways
of B6 vitamer metabolism; (ii) drugs and other compounds that bind to PL kinase and
inhibit its activities; (iii) drugs and other compounds that react with PLP and/or other B6
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vitamers and inactivate it; (iv) inborn errors that lead to accumulation of small molecules
that react with PLP and/or other B6 vitamers and inactivate it; (vi) renal dialysis, which
leads to increased losses of B6 vitamers; and (vii) inborn errors affecting specific PLPdependent enzymes.51, 52
1.10 PL kinase inhibitors and PLP deficiency: Several drugs, as well as natural
compounds are known to lead to PLP deficiency with concomitant neurotoxic effects.53-61
Some of these compounds are known to inhibit PL kinase activity, which has been
suggested to be the cause of the PLP deficiency.53,

55, 59-61

Significant decreases in the

serum concentration of PLP have been described in epileptic patients treated with
anticonvulsant drugs (e.g., phenobarbital, phenytoin, carbamazepine, and valproic acid),
which is reflected in reduction in the enzymatic activities of aspartate aminotransferase and
alanine aminotransferase, two PLP-dependent enzymes.62 Theophylline has been shown to
significantly decrease plasma PLP levels in rabbits, asthmatic patients, or in healthy
volunteers, resulting in peripheral neuropathy, seizures (acute overdose), sleeplessness,
headache, restlessness, agitation, tremors and hallucinations.54-58 A plasma concentration
of theophylline greater than 110 µM is reported to be associated with these symptoms.63
4’-O-methylpyridoxine (an analog of vitamin B6), found in Ginkgo biloba seeds leads to
significant B6 deficiency in mammals, resulting in convulsion, unconsciousness and other
neuronal symptoms similar to that of theophylline.64 This supplement is easily available
over the counter and there is great concern over its unsupervised use.
Other drugs, including cycloserine and isoniazid, pyrazinoic acid, dopamine,
penicillamine are also known to inhibit PL kinase resulting in many neurological side
11

effects (similar to those of theophylline).53,

55, 59-61, 65

It is also known that a significant

number of women using oral contraceptives who did not take B6 supplements were found
to be deficient in PLP.52 Pyridoxine is usually prescribed to patients to prevent the
associated neurotoxic side effects of some of these PL kinase inhibitors.63,

65-69

Also,

administration of vitamin B6 to mice treated with theophylline is known to reduce the
number

of

seizures;

and

in

rabbits,

vitamin

B6 reversed

the

changes

in

electroencephalograms caused by high doses of theophylline.61, 65, 66 A recent study found
that Roscovitine, an inhibitor of cyclin-dependent kinases, showed moderate inhibitory
activity against PL kinase.70, 71 Kinetic studies have been used to investigate the inhibitory
effects of some of the above mentioned drugs.55 There are several unanswered questions,
including whether other compounds that exhibit theophylline neurotoxic effect could be
doing so by inhibiting PL kinase activity. Also, it is not known how these PL kinase
inhibitors affect B6 pools in the cell.
1.11 Genetic defects in PL kinase or PNP oxidase and PLP deficiency: Human
PL kinase and Human PNP oxidase genes are located on chromosomes 21q22.3 and
17q21.2, respectively. The autoimmune polyglandular disease type 1 has been linked to
errors in chromosome 21q22.3. Patients show abnormal B6 metabolism.72 Four identified
genetic defects in chromosome 17q21.2 result in mutations in the PNP oxidase enzyme, all
of which reduce or completely abolish PNP oxidase activity leading to neonatal epileptic
encephalopathy (NEE).73-76 An example is a missense mutation (R229W) that leads to
NEE. A recent study has elucidated the molecular basis of the reduced PNP oxidase
R229W catalytic activity, which was found to be due to weak binding of the oxidase
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cofactor, FMN, as well as the substrate, PNP. Based on their study, the investigators
suggested that the use of riboflavin (vitamin B2 or FMN) and pyridoxine, in conjunction
with pyridoxal may offer some improvement over the current treatment protocol of PL or
PLP alone due to the apparent loss of FMN from the PNP oxidase R229W variant.77
Several other studies have also reported strong association between other
neurological disorders, including seizures, autism, attention deficit hyperactive disorder,
Alzheimer’s, Parkinson’s, learning disability, anxiety disorders and PLP deficiency.68, 75, 7883

There has been considerable interest in treating the symptoms of some of the above

disorders with vitamin B6, however, studies on the effect of B6 supplementation show
conflicting results. Consistently, administration of PN to patients with NEE failed, while
PL/PLP offered some relief, supporting the location of the defect in PNP oxidase, as PL
kinase is able to act on PL and convert it to PLP in the brain.73, 75 Although, there is no
direct evidence linking some of these neurological disorders to mutations in either the
kinase or oxidase, these genes are clearly candidates for mutational analysis in affected
patients. If such an error is identified, studies could be performed to investigate the role of
the mutation in the enzymatic activity and the associated phenotypes. These studies could
point to the correct pharmacologic intervention.
1.12 Other disorders associated with vitamin B6 deficiency:

Other non-

neurological disorders are known to be caused, or have been suggested to be caused, by
vitamin B6 deficiency, including but not limited to the following - anemia, inability to
maintain normal blood sugar levels, immune disorders and cardiovascular diseases. This is
because PLP dependent enzymes are involved in heme synthesis, conversion of stored
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carbohydrate to glucose to maintain normal blood sugar levels, homeostasis of
homocysteine (a factor in cardiovascular diseases), and production of lymphocytes and
interleukin-2.76, 84-88
1.13 Conclusion: PLP is used by several apo-B6 enzymes as a co-factor to form the
catalytically competent holo-enzymes serving vital roles in various transamination,
decarboxylation, and synthesis pathways involving carbohydrates, sphingolipids, amino
acids, heme and neurotransmitters. Thus vitamin B6, in its active PLP form, supports more
vital bodily functions than any other vitamin, yet little information is currently available on
the mechanism of the regulation of PLP and vitamin B6 metabolism, and how PLP is
distributed among the dozens of competing apo-B6 enzymes involved in neurotransmitter
synthesis as well as other physiological functions. 20-24 On the other hand, disruption of the
B6 salvage pathway due to pathogenic mutations in PNPOx or PL Kinase or inhibition of
these two enzymes or lack of nutritional intake of vitamin B6 is known to result in PLP
deficiency, which has been implicated in several pathologies including seizures, autism,
Down’s syndrome, schizophrenia, autoimmune polyglandular disease, Parkinson’s,
Alzheimer’s, epilepsy, ADHD and learning disability.73-76,

78, 89-91

Some drugs are also

known to cause PLP deficiency by inhibiting PL kinase with concomitant neurotoxic
effects.53-61 It is likely that other drugs and natural products that cause similar side effects
could also be inhibiting PL kinase.
Our goal is to understand the catalytic function of PL kinase and the regulatory
pathway of vitamin B6 metabolism. To achieve our goal the study was divided into four
specific aims, including: (1) Determine the kinetic and structural properties of PL kinase;
14

(2) Determine the role of the active site residue Asp235 in PL kinase catalytic function; (3)
Determine the method of kinetic regulation of PL kinase; and (4) Identify drugs and other
compounds that are inhibitors of PL kinase.
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CHAPTER 2
Determine the Kinetic and Structural Properties of
Human PL Kinase

2.1 Introduction: PL kinases have been purified from bacterial, plant, and
mammalian sources and evidence suggests that most eukaryote organisms contain a single
PL kinase, coded by a pdxK gene. However, a large number of prokaryotes expressing PL
kinases coded by both pdxK and pdxY genes have been reported.7-8 While the enzyme
coded by the pdxY gene is inactive, in the presence of MgATP, PL kinase coded by the
pdxK gene catalyzes the addition of phosphate to the 5’ alcohol of PN, PM and PL to form
PNP, PMP and PLP, respectively and ADP.4 The mechanism of phosphorylation has been
elucidated for the sheep and E. coli PL kinase enzymes, and follows a random sequential
substrate addition. 11-12
Metals, both monovalent and divalent cations, are known to be absolute
requirements for the mechanistic function of many PL kinases, providing driving forces for
ATP binding and substrate catalysis. 7-8, 11-12 In E. coli PL kinase, the metal ion tandem
Mg2+ and K+ are required for enzyme activity. In contrast, Zn2+ and K+ have been proposed
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to be the physiological metals needed by both human PL kinase (hPL kinase) and sheep PL
kinase for activity.7-8, 11-12 However, a more recent study with the human enzyme clearly
showed that under non-physiological substrate concentrations and/or at pH 6, where these
previous assays were performed, Zn2+ does stimulate the activity, but under physiological
conditions at pH 7.3, Mg2+ is the required divalent metal ion and Zn2+ inhibits the
reaction.92
In order to understand the catalytic properties of hPL kinase and to characterize the
role of the monovalent and divalent cations in the catalytic mechanism of hPL kinase, we
expressed and purified hPL kinase and performed detailed kinetic and structural studies of
hPL kinase.

2.2 Methods
2.2.1 Expression and purification of human PL kinase: Competent E. coli
Rosetta (DE3)pLysS cells (Novagen) were transformed with a pET22b vector carrying the
human pdxK gene insert. Transformants were grown in 6 L of Luria broth (LB) broth and
after reaching an O.D.600nm of 1.2 were induced with 0.5 mM Isopropyl β-D-1thiogalactopyranoside (IPTG). Cells were grown for an additional 5 h at 30°C and
harvested by centrifugation. The cell pellet was suspended in 200 mL of potassium
phosphate buffer, pH 7.2, and ruptured by high pressure homogenization in an AVESTIN
cell disrupter. Streptomycin sulfate was added to a final concentration of 10 g/L to remove
excess nucleic acid. After an ammonium sulfate fractionation, and dialyzing the enzyme
against

20

mM

potassium

phosphate

buffer,
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pH

7.2,

it

was

purified

on

Trimethylaminoethyl (TMAE), phenyl sepharose, and hydroxyapatite columns.92 The
purity was >95%, as judged by SDS-PAGE.
2.2.2 Determination of kinetic constants of PL and MgATP: Human PL kinase
enzyme used in the kinetic experiments were dissolved and dialyzed overnight against 20
mM sodium BES [N,N-bis(2-hydroxyethyl)-2-amino-ethanesulfonic acid] buffer, pH 7.2.
All assays were performed at 37ºC in a 1-cm thermostated cuvette. Initial velocity studies
for the conversion of PL to PLP were followed at 388nm in an Agilant 8454
spectrophotometer in 20 mM sodium BES buffer, pH 7.2. 9, 92 MgATP concentrations were
varied between 200 µM and 1200 µM, and PL concentrations between 25 µM and 1 mM.
Binding constants of PL and MgATP were determined by double reciprocal plots.
2.2.3 Human PL kinase activity in the presence of monovalent cations: Human
PL kinase used in this kinetic experiment was extensively dialyzed against 20 mM
triethanolamine BES, pH 7.2, prior to performing assays. All assays were performed in 20
mM triethanolamine BES, pH 7.2, and containing added monovalent salts from 0–50 mM
at saturating ATP and PL concentration. All reagents used in the assays were dissolved in
20 mM triethanolamine BES, pH 7.2.9
2.2.4 Crystallization and structure determination of human PL kinase: Human
PL kinase protein was dialyzed overnight against 20 mM K phosphate buffer (pH 7.0)
containing 100 mM NaCl and then concentrated to 18 mg/mL (0.5 mM). Crystallization
drops composed of 2 µL of protein solution and 2 µL of reservoir and equilibrated against
700 µL reservoir solution (100 mM Tris-HCl, pH 8.0, and 50% MPD) resulted in
rectangular-shaped crystals. Crystallization of hPL kinase in the presence of 2 mM
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MgATP was also attempted under similar conditions. The complex mixtures were first
incubated on ice for about 3–4 hr before screening for crystallization.
For X-ray data collection, crystals were cryoprotected in solution containing 100
mM Tris-HCl buffer (pH 8.0) and 60% MPD with or without the MgATP before flash
cooling in a cryogenic nitrogen stream. X-ray data were collected at 100 K using a
Molecular Structure Corporation (MSC) X-Stream Cryogenic Crystal Cooler System and
an R-Axis IV++ image plate detector, a Rigaku MicroMax–007 X-ray source equipped
with MSC Varimax confocal optics operating at 40 kV and 20 mA. Crystals of hPL kinase
in unliganded form diffracted to 2.0 Å The hPL kinase grown in the presence of MgATP
diffracted to 2.2 Å. The data sets were processed with the MSC d*TREK software
program. The Matthews Coefficient of 3.2 and water content of 61% are consistent with
one dimer per asymmetric unit.
The crystal structure of the unliganded hPL kinase was solved using the Web-tool
CaspR, which executes an optimized molecular replacement procedure.93 The hPL kinase
sequence and the search models of shPL kinase (PDB code 1LHP; 87% sequence identity
to human PL kinase) and ePL kinase (PDB code 2DDM; 24% identity) were first used to
derive multiple structure-sequence alignments with the program T-Coffee,94 followed by
homology model building with the program MODELLER.95 Fifteen models were
generated with different spatial conformations, and each was automatically screened in
CNS. 97 Two of the models had the best convergence, with correlation coefficients of about
0.66 and R-factors of 0.40. The next best solution had a correlation coefficient of 0.40 and
an R-factor of 0.53.
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The model from the converged solution was used for subsequent structure
refinement, by means of CNS, with a bulk solvent correction. The starting model was
subjected to rigid body, positional, and simulated annealing refinements with all 2.0 Å
crystallographic data to Rwork/Rfree of 33.5% / 38.5%. Some residues were omitted due to
weak densities. The model was subsequently adjusted, followed by further cycles of
refinements and addition of Na+, PO42−, MPD, and water molecules.
The partially refined hPL kinase structure without solvent molecules and metal ions
was used as the starting model to refine against the diffraction data from the cocrystals of
hPL kinase and MgATP. Initial rigid body, positional, and simulated annealing
refinements at 2.2 Å resolution to Rwork/Rfree of 26.2% / 32.2% clearly showed ATP, Mg2+
and Na+ bound at the active site of the complex, which were modeled in the structure. The
refinement statistics are summarized in Table 1. Atomic coordinates and structure factors
have been deposited in the RCSB Protein Data Bank with the accession codes 2YXT and
2YXU for the unliganded and MgATP-bound hPL kinase, respectively. 9
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Table 1. Data collection and refinement statistics for the hPL kinase crystals.

Data collection
Space group
Unit cell a, b, c (Å)
Resolution (Å)a
Unique reflections
Mean redundancy
Completeness (%)
Average I / σ(I)
Rmergeb
Refinement statistics
Rwork (95% data)c
Rfree (5% data)d

Unliganded

MgATP

I222
90.63, 115.29, 172.40
30 - 2.0(2.07 - 2.00)
60825(6055)
4.7(4.5)
99.3(99.9)
11.9(4.4)
0.073(0.340)

I222
90.46, 115.12, 170.20
30 – 2.2 (2.28 – 2.20)
44337 (4270)
6.7(6.6)
97.6(95.9)
14.5(5.2)
0.082(0.366)

0.206(0.448)
0.245(0.473)

0.192(0.388)
0.243(0.415)

Average B (Å2) / No. of non-H atoms
Protein
38.6 / 4797
38.5 / 4842
Water
52.2 / 518
53.0 / 474
MPD
69.6 / 112
68.8 / 96
Anion (PO42-)
97.9 / 30
97.7 / 25
62.3 / 2
26.6 / 4
Cation (Na+, Mg2+)
ATP
34.0 / 62
_______________________________________________________________________
a

Numbers in parentheses refer to the outer (highest) resolution shell.

b

Rmerge = ∑|I -〈 I〉 |/∑(I), where I is the observed intensity and 〈 I〉 is the weighted mean
of the reflection intensity.
c
Rwork = ∑||Fo| -Fc|| / ∑|Fo|, where Fo and Fc are the observed and calculated structure factor
amplitudes, respectively.
d
Rfree is the crystallographic Rwork calculated with 5 % of the data that were excluded from
the structure refinement.
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2.3 Results and Discussion
2.3.1 Kinetic constants and synergism between PL and ATP: Using pig brain
extracts of PL kinase, Churchich and Wu first showed that the phosphorylation reaction
catalyzed by PL kinase with MgATP result in significant amounts of the binary complexes
of enzyme-ATP and enzyme-pyridoxal.13 Recent kinetic and structural studies with sheep,
human and E. coli enzymes are consistent with this random sequential substrate addition
mechanism.7-8, 11-12, 92 The question we ask is whether there is any synergism in the binding
of ATP and PL. If MgATP and PL bind randomly, and binding of one substrate changes
the binding constant for the other substrate by a factor α, the hPL kinase system can be
described by the equilibria shown below (Figure 8).98

KB

E.PL

ATP

αΚA

PL
E
ATP

KA

E.PL.ATP

αΚΒ
E.ATP

E.PLP.ADP

PL

Figure 8: Binding equilibria for human PL kinase substrates

The complexes E.ATP, E.PL, E.PL.ATP, and E.PLP.ADP are transitory
complexes. KA and αKA are binding constants for ATP in the absence of PL and infinite PL,
respectively. KB, and αKB are binding constants for PL in the absence of ATP and infinite
ATP, respectively. The binding constants were determined from double reciprocal plots of
initial rates with PL and MgATP as the variable and fixed substrates. In general, each
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substrate was varied over a 10-fold concentration range. The pattern of lines in the doublereciprocal plots crossed at a point above the negative x axis when either ATP or PL was
the variable substrate (Figures 9 and 10). The 1/initial rate versus 1/[ATP] plot at different
fixed concentration of PL or vice versa were drawn to calculate the values of KA and KB,
respectively.
Apparent initial rate values, calculated from plots of 1/intial rate versus 1/[PL] at
different fixed concentration of ATP, were plotted against the corresponding 1/[ATP] to
determine αKA (Figure 11 ). Similarly, apparent initial rate values, calculated from plots of
1/intial rate versus 1/[ATP] at different fixed concentration of PL, were plotted against the
corresponding 1/[PL] to determine αKB (Figure 12 ). Values of KA, KB, αKA, and αKB are
shown in Table 2. The factor α which describes synergistic behavior between the substrates
is ~0.31, and is calculated using the equation 1.
α = [αKA] / [KA]

or

α = [αKB] / [KB]-------------------- Equation 1

Since α is less than unity, it indicates binding of ATP increases the affinity of
human PL kinase for the PL or vice versa.98

Table 2: Kinetic parameters of human PL kinase substrates (in µM)
KA

KB

αKA

αKB

833

95

266

30.5

23
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5.5
5
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200 uM PL
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2
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1
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0
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2 2.5

3 3.5
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Figure 9: Determination of KA
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0.01

0.02

0.03

1/ PL ( uM)

KB
-5

Figure 10: Determination of KB

24

0.04

0.05

3

αKA = Slope x 1/Vmax
y = 285.46x + 1.0723

1/ Vmax-app ( Minute)

2.5

2

1.5

1

0.5

0
-0.005

-0.0025

0

0.0025

0.005

0.0075

1/MgATP ( uM)

-0.5

1/ Vmax-app ( Minute)

Figure 11: Determination of αKA
αKB = Slope x 1/Vmax
y = 28.541x + 0.933

1.6

1.2

0.8

0.4

0
-0.04

-0.03

-0.02

-0.01

0

0.01

1/PL ( uM)

Figure 12: Determination of αKB
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0.02

0.03

2.3.2 Effect of different monovalent metals on human PL kinase activity: We
measured enzyme activity using a variety of monovalent cations under saturating PL and
MgATP concentrations, and found that both Na+ and K+ activated the hPL kinase while
other monovalent cations, Li+, Cs+, and Rb+ do not show significant activity (Figure 13).9

Figure 13: Activity of human PL kinase in the presence of either Na+ or K+.
(Closed circles for Na+ & triangles for K+).

2.3.3 Structural Studies - Crystal structures of human PL kinase, as well as its
complex with MgATP were determined at resolutions of 2.0 Å and 2.2 Å, respectively, to
understand the kinetic properties of PL kinase on molecular level. The two crystals are
isomorphous, and both belong to the orthorhombic space group I222. The asymmetric unit
of both structures contains monomers A and B, which are related by a noncrystallographic
dyad axis. Each monomer of hPL kinase consists of nine α-helices and 11 β-strands
(Figure 14A).
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The unliganded shPL kinase, and ePL kinase crystal structures have been reported
at ~ 2.1 Å resolution, while the corresponding MgATP complexes of shPL kinase and ePL
kinase have also been reported at 2.6 Å resolution. All these PL kinase structures show the
same typical ribokinase superfamily central core of β-sheets surrounded by α-helices, as
well as similar dimeric assembly.7-8, 11-12 A structure of the hPL kinase dimer is shown in
Figure 14B. The overall structures of hPL kinase and hPL kinase-MgATP are very similar.
The dimers (for 577 Cα pair atoms) or monomers (for 299 Cα pair atoms) superimpose on
each other with an RMSD of 0.37 Å, which compares with ~0.35 Å between monomers
within each structure. This indicates that binding of ATP at the active site does not induce
larger conformational changes than exists between two monomers within the same crystal.
Similar observations were also reported for the ePL kinase and shPL kinase structures.7-8,
11-12

In the unliganded hPL kinase crystal, we observed bound Na+ in both active sites,
close to where the ATP γ-phosphate group is located in the hPL kinase–MgATP complex
(Figure 15). The Na+ is penta-coordinated with water molecules (average distance of 2.1
Å). The water molecules are in turn hydrogen-bonded to the side chains of Asp113,
Glu153, and Thr186, as well as the amide nitrogen and oxygen atoms of Asn150 and
Thr148, respectively (Fig. 15A). The unliganded hPL kinase model also contains 14 MPD
molecules, located in the active sites, on the surface of the protein at various crevices, as
well as the interfaces of crystal contacts. Interestingly, three MPD molecules span across
the PL (MPD 3) and ATP (MPD 1 and MPD 2) binding cavities in each of the monomers
of hPL kinase, mimicking the substrate molecules (Fig. 15B).
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Figure 14: Overall structure of hPL kinase. (A) The monomeric structure with bound ATP (stick),
MPD (stick), Na+ (brown sphere), and Mg2+ (magenta sphere) at the active site. α-Helices and βstrands are colored yellow and red, respectively. The secondary structures are labeled. (B) The dimeric
structure, also with bound ATP (cyan CPK), MPD (gray CPK), Na+ (brown sphere), and Mg2+
(magenta sphere). Monomers A and B are colored red and yellow, respectively.

Each of the two active sites in the liganded hPL kinase–MgATP complex binds
ATP, Mg2+, and Na+ molecules. The ATP γ-phosphate group and the two metal ions, Na
and Mg are remarkably well defined in both active sites (Figures 16C,D). Comparison of
hPL kinase and hPL kinase–MgATP structures shows that residues 224–228, which form
part of the loop region between strand β11 and helix α7 have rotated away from the active
site to allow binding of the ATP adenine (Figure 15B). Additionally, the active site
structure formed by the strand β6-Loop I–strand β7, which is referred to as a flap in PL
kinases, has moved closer to the bound ATP (Figure 15B). The mode of ATP–protein
interaction is depicted in Figure 16A, which is similar to those described for shPL kinase
and ePL kinase.7-8,

11-12

Of note is that all the residues that make contact with the β-/γ28

phosphate groups are totally conserved in PL kinases.7-8,

11-12

Binding of ATP has also

displaced two MPD molecules (MPD 1 and MPD 2 in Figure 15B) observed at the ATP
binding site in the unliganded structure. Like the unliganded structure, we still observed a
MPD molecule bound at the PL binding site (MPD 3 in Figure 15B).
The Mg2+ in hPL kinase is located between the ATP α- and β-phosphate groups and
it’s octahedrally coordinated (Figures 15C) - two ligands from the ATP α/β-phosphate
groups (~2.1 Å), a ligand each from the carboxyl oxygen of Asp118 (~2.2 Å) and the
hydroxyl of MPD (~2.3 Å), and two water molecules (~2.2 Å). The high charge density of
Mg2+ is thus balanced by the negatively charged carboxyl and phosphoryl groups, and most
importantly, the Mg2+ location is consistent with its function by binding to the bisphosphate moiety to neutralize the negative charges and stabilize the ADP leaving group
during the phosphorylation reaction.
Binding of ATP has displaced the bound Na+ in the unliganded hPL kinase by ~2.0
Å to another position (Figure 16B). Unlike the unliganded structure, the Na+ in the
complex now makes direct bond contacts with the protein and the ATP (Figure 16C). The
coordination of the Na+ in hPL kinase-MgATP appears to be trigonal–bipyramidal or
square–pyramidal (Figure 16C), with two donor atoms from the ATP γ-phosphates group
(~2.5 Å), one donor atom from the amide oxygen of Thr148 (~2.4 Å), and one donor atom
from the hydroxyl of Thr186 (~2.3 Å), and a water molecule (2.3 Å). Our studies with the
monovalent cations show that Na+ and K+ activated the enzyme significantly with the
former showing more activation. In the structural studies of sheep PL kinase, K+ instead of
Na+ was used to crystallize the sheep enzyme.11-12 Comparison of the sheep and our human
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PL kinase structures show K+ and Na+ positions overlap (Figures 16B). Nevertheless,
while Na+ has a five-coordination shell in the human enzyme, K+ in the sheep enzyme is
octahedrally coordinated with the protein residues Thr186, Asp113, Glu153, and Thr148,
as well as the ATP β-phosphate group and a water molecule. Thus, when K+ is replaced by
Na+ in the human enzyme only the interactions with Thr148 and Thr186 are conserved,
and contributions from Asp113 and Glu153 are lost. In both structures, the two metal ions,
through their direct interaction with the protein and ATP phosphate groups, should be able
to engage and anchor the ATP for catalysis.
The question remains as to why the human enzyme is more active in the presence
of Na+ than K+. It is possible that replacement of K+ with Na+ changes the geometry of the
active site to a more optimal orientation of catalytic residues, leading to greater enzyme
activity in the presence of the later cation. This is consistent with several studies that
suggest that coordination sphere of metal cations plays a significant role in enzyme
activity.99-102 In dialkylglycine decarboxylase, replacement of Na+ with K+ is known to
drastically change the geometry of coordination and perturbs residues that control binding
of substrate.99-100 In thrombin, changes in coordination sphere of Na+ and K+ is known to
affect the oxyanion hole geometry explaining the differences in kinetic activity.101 In some
proteins, however, replacement of one metal with another, such as K+ with Na+ in pyruvate
kinase, results in no structural change even though the enzyme is inactive in the absence of
K+.102
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Figure 15: Structural basis of monovalent and divalent ions' activation of hPL kinase. (A) Na+
(brown sphere) bound to the active site of monomer A of unliganded hPL kinase. (B) Stereoview of
the superimposed active sites of unliganded hPL kinase (colored yellow) and hPL kinase-MgATP
complex (colored cyan). Three MPD molecules occupy the active site of the unliganded hPL kinase
structure, whereas two are found in the hPL kinase–MgATP complex. (C) Na+ (brown sphere) and
Mg2+ (magenta sphere) binding modes at the active site of hPL kinase–MgATP complex
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Figure 16: The active site and substrate of hPL kinase–MgATP complex. (A) Schematic diagram
showing interactions between Na+, Mg2+, ATP, and the protein residues of hPL kinase.(B)
Stereoview of the superimposed active sites of hPL kinase–MgATP (colored yellow) and shPL
kinase–MgATP (colored red). (C) A Fo−Fc map (contoured at the 3.0 σ level) of Na+, Mg2+, and
ATP of the hPL kinase–MgATP complex, calculated before the metal ions and ATP were added to
the refined model. (D) A 2Fo−Fc map (contoured at the 1.0 σ level) of Na+, Mg2+, and ATP of the
hPL kinase–MgATP complex. Both maps are superimposed with the final refined models.
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It should be recalled that in unliganded hPL kinase, there is a bound Na+, which is
penta- or tetra- coordinated with solvent molecules (Figure 15A), however binding of ATP
displaces the Na+ to another position, closer to the protein, where it makes direct
interaction with the protein in addition to the ATP (Figure 15B and C). Note that the Bvalues of the Na+ ions in the unliganded crystal (~60 Å2) are much higher than those in the
MgATP complex (~30 Å2), suggesting stable binding with the mediating waters excluded.
It’s known that substrate binding to a stabilized enzyme-M+ complex is more favorable as
the entropic penalty of ordering the enzyme to form the enzyme-substrate complex is offset
by the previously bound M+.103 This is consistent with the observed increased affinity for
ATP in the kinases. Nevertheless, due to the small size of Na+ (0.9 Å), it should form a
relatively strong interaction with 4 or 5 solvent molecules, while the larger K+ (1.33 Å)
should prefer more solvent molecules with relatively weaker interactions. The ability to
strip off water molecules from the hydration sphere should therefore be easier with K+ than
with Na+, and could explain why the enzyme shows greater affinity for ATP in the
presence of K+ than Na+.104-106
A known K+ position in the E. coli enzyme would help throw light on the structural
basis of the M+ selectivity in ePL kinase. However, it seems that human and perhaps other
eukaryote PL kinases have evolved K+ selectivity by imposing 6-coordinate geometric
constraint on the coordination sphere that may not be accessible by Na+. In some
ribokinase superfamily enzymes, the monovalent cation does not make contact with the
protein but only with the ATP, and it’s believed that the cation exerts its influence
indirectly by perturbing the conformation of the active site residues.107-108 On the other
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hand, in some PLP-dependent enzymes, such as serine hydratase,109 tryptophanase110, the
M+ does not make contact with the substrate, but aids to organize the architecture of the
active site for catalysis.109A recent mini review article elegantly classified the enzymes that
have a monovalent cation bound to ATP and the protein residues as M+-activated Type I,
while those that bind only to either the protein or the substrate as M+-activated Type II.103
PL kinases obviously belong to the former, while other non-PL kinase members in the
ribokinase superfamily of proteins, such aminoimidazole riboside kinase107 belong to the
latter. Thus the binding mode of monovalent cations may be an indicator as to how these
species have evolved from each other.

2.4 Conclusion
Pyridoxal kinase catalyzes the transfer of a phosphate group from ATP to the 5′
alcohol of pyridoxine, pyridoxamine, and pyridoxal. In this work, we report kinetic
constants for hPL kinase substrates, PL and ATP and kinetic studies were conducted to
examine monovalent cation dependence of hPL kinase kinetic parameters. The kinetic
study suggests synergistic binding of Mg-ATP and PL, which could be important in the
regulation of PL kinase activity. We have also determined the crystal structure of hPL
kinase in the unliganded form, and in complex with MgATP to elucidate the molecular
basis of monovalent and divalent ions activation of the enzyme.9 The crystal structure
reveals Mg2+ and Na+ acting in tandem to anchor the ATP at the active site. The structure
also suggests that differences in PL kinase activity in the presence of different monovalent
ions could be due to differences in the coordination sphere of the ions. It is quite possible
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that under physiological conditions in the cells, where K+ is several fold higher than Na+,
the enzyme will be in its K+ form.
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CHAPTER 3
Determine the Role of the Active Site Residue Asp235 in
PL Kinase Catalytic Function

3.1 Introduction: The crystal structures of Escherichia coli, sheep and human PL
kinases reveal a functional dimeric structure, with one active site per each monomer. PL
kinases are classified as members of the ribokinase superfamily, since they show the same
typical central core tertiary structures of β-sheets surrounded by α-helices, as well as
conserved ATP and substrate binding site geometries.7-9,

11-12

Members of this enzyme

superfamily catalyze the phosphorylation of the C5′-hydroxyl group of their respective
substrates using ATP. In PL kinases and in the ribokinase superfamily as a whole, a
conserved Asp235 residue is observed to make a hydrogen-bond interaction with the C5′OH group of the substrates, and the current working hypothesis suggests this residue to be
the base that deprotonates the C5′-OH group, with the resulting negatively charged O5′
atom making a direct nucleophillic attack on the ATP γ-phosphate (Figure 17).7-9, 11-12
In this study, three site-directed mutant forms of human PL kinase, including
D235H, D235A and D235N were constructed, however only the latter two could be
expressed and purified. Kinetic and structural studies were carried out to determine if
Asp235 plays a catalytic role in PL kinase enzymatic activity.
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Figure 17: Proposed reaction mechanism by PL kinase.

3.2 Methods
3.2.1 Site-directed mutagenesis and purification of enzymes: The D235A and
D235N mutants were made on the wild-type construct pET22b(+) carrying the human
pdxK gene insert91 using the QuickChange™ Site-Directed Mutagenesis Kit from
Stratagene (La Jolla, CA). The mutations were confirmed by sequencing the cDNA inserts.
The mutated and wild type gene inserts were then transferred into a pET28a(+) vector by
use of NdeI and XhoI unique restriction sites, and then transformed into E. coli Rosetta
(λDE3) pLysS competent cells for protein expression (Novagen).
The Rosetta cells with the wild type and mutated genes were grown in 6L of LBkanamycin–chloramphenicol medium to an optimal density of 1.2 at 600 nm, and then
induced with 0.5 mM IPTG. Cells were grown for an additional 5 h at 32 °C and harvested
by centrifugation. The cell pellets were resuspended in 250 ml of 50 mM sodium
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phosphate buffer, pH 8.0, and disrupted by high pressure homogenization in an AVESTIN
cell disrupter. Streptomycin sulfate was added to a final concentration of 10 g/L to remove
excess nucleic acids. The enzyme was dialyzed in 50 mM sodium phosphate buffer, pH
8.0, and then purified using a Ni-NTA (Nickel-nitrilotriacetic acid) column. Fractions
containing 95% purity, as judged by SDS-PAGE were pooled and concentrated.16
3.2.2 Determination of kinetic constants: Wild-type, and D235A and D235N
mutants used in the kinetic experiments were dialyzed overnight against 20 mM sodium
BES buffer, pH 7.2. Kinetic assays were performed at 37 °C in a 1 cm thermostated
cuvette. Initial velocity studies for the conversion of PL to PLP were followed at 388 nm in
an Agilant 8454 spectrophotometer in 20 mM sodium BES buffer, pH 7.2.9,

92

MgATP

concentrations were varied between 100 to 800 µM, and PL concentrations between 20 to
300 µM. The Km and kcat values for PL and MgATP were determined by double reciprocal
plots.
3.2.3 Crystallization, data collection and structure determination: The D235A
mutant was co-crystallized with PL and ATP, while D235N mutant was co-crystallized
with ATP. Crystallization drops were composed of 2.5 µL of protein solution (with
2.5 mM MgATP and/or 1 mM PL) and 2.5 µL of reservoir and equilibrated against 700 µL
reservoir solution (100 mM Tris–HCl, pH 8.0, and 57% MPD, 5 mM MgSO4).
Crystals were cryoprotected in solution containing 100 mM Tris–HCl buffer (pH
8.0) and 60% MPD with the appropriate substrates before flash cooling. X-ray data were
collected at 100 K using a Molecular Structure Corporation (MSC) X-Stream Cryogenic
Crystal Cooler System and an R-Axis IV++ image plate detector, a Rigaku MicroMax–
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007 X-ray source equipped with MSC Varimax confocal optics operating at 40 kV and
20 mA.
The isomorphous human PL kinase structure (PDB code 2YXT)9, mutating
Asp235 to Gly, and omitting bound ATP, phosphate, water and MPD molecules was used
as the starting model for the refinements of the two mutant structures. All refinements
were performed with the CNS program. 97
After rigid body refinement, conjugate gradient minimization and simulated
annealing using the diffraction data of D235A, difference density at residue 235 suggested
an Ala consistent with nucleotide sequencing result. Densities were also identified for
ATP, Mg2+ and Na+ in both active sites. We also observed bound PLP and PL molecules
in the active site of subunit B and bound PL and sulfate molecules in the active site of
subunit A. In the D235N mutant, after a similar refinement cycle, using a model with
residue 235 as Gly, we observed a density extending from the α-carbon of residue 235
suggesting an Asn mutation. We also observed bound ATP and sulfate molecules in the
active sites. The two complexes were refined with alternate cycles of conjugate gradient
minimization, simulated annealing and B-factor refinements with intermittent model
rebuilding using both TOM and COOT.111, 112
Addition of water, MPD and sulfate molecules led to the final crystallographic
Rwork/Rfree of 21.2%/26.2% for the 2.5 Å resolution D235A structure; and 21.4%/26.1% for
the 2.3 Å resolution D235N structure. The structure solution/refinement statistics are
shown in Table 3. Atomic coordinates and structure factors have been deposited in the
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RCSB Protein Data Bank with codes 3FHX and 3FHY for D235A and D235N,
respectively.16
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Table 3: Crystal information, data collection and refinement parameters of
D235A and D235N mutants

Data collection statistics
Space Group
Cell Dimensions (Å)
Resolution (Å)a
No. of measurements
Unique reflections
I/sigma I
Completeness (%)
Redundancy
Rmerge (%)b
Structure refinement
Resolution limit (Å)
No. of reflections
Rwork (%)c
Rfree (%)d
Rmsd standard Geometry
Bond-lengths (Å)
Bond-angles (°)
Dihedral angles
Most favored regions
Additional allowed regions
Bfactors
All atoms
Protein alone
ATP
Metal ions
Sulfate
Water
MPD
a

D235A

D235N

I222
91.2 115.4 168.9
32.69-2.5 (2.59-2.5)
124056
31128 (2935)
10.9 (4.2)
99.7 (99.6)
3.99 (3.79)
8.3 (29.8)

I222
91.1 114.6 169.7
32.54-2.30 (2.38-2.30)
133496
39415(3745)
15.5 (4.6)
99.0 (99.3)
3.39 (3.18)
4.9 (25.0)

29.93-2.5 (2.59-2.5)
31124 (2935)
21.2 (38.9)
26.2 (40.3)

29.36-2.30 (2.38-2.30)
39410 (3745)
21.4 (38.2)
26.1(43.8)

0.008
1.4

0.008
1.4

93.45
5.73

93.85
5.32

43.8
43.2
40.7
35.3
72.3
40.1
75.7

44.22
43.40
38.45
28.42
74.07
45.82
72.23

Numbers in parentheses refer to the outer (highest) resolution shell.

b

Rmerge = ∑|I -〈 I〉 | /∑(I), where I is the observed intensity and 〈 I〉 is the weighted
mean of the reflection intensity.
c
Rwork = ∑||Fo| -Fc|| / ∑|Fo|, where Fo and Fc are the observed and calculated structure factor
amplitudes, respectively.
d
Rfree is the crystallographic Rwork calculated with 5 % of the data that were excluded from
the structure refinement.
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3.3 Results and Discussion:
Three mutants D235H, D235A and D235N were constructed but only the latter two
could be expressed and subsequently purified. The D235A mutant showed a 15-fold
decrease in catalytic activity, as well as a 7-fold decrease in affinity for PL (Table 4). The
D235N mutation resulted in a

2-fold decrease in activity and PL affinity (Table 4). The

Km for MgATP did not change significantly between the wild-type and mutant enzymes
(~200 uM), consistent with the fact that the carboxylate of Asp235 makes a hydrogen-bond
interaction with PL but not with ATP.12

Table 4: Kinetic parameters for hPL kinase wild type and D235A and D235N
mutants

Enzyme

Wild Type

D235N

D235A

Km, Pyridoxal

24 µM

58 µM

170 µM

kcat

29.37 Min-1

14.39 Min-1

1.9 Min-1

X-ray structures of D235A and D235N mutants were determined to 2.5 and 2.3 Å,
respectively. The D235A mutant structure, co-crystallized with PL and ATP, showed these
two substrates, as well as the product PLP bound simultaneously at the subunit B active
site (Figure 18A and B). In subunit A, we also observed PL and ATP, but instead of PLP,
we found a bound sulfate molecule that occupies the PLP phosphate position.
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The D235N mutant, co-crystallized with ATP, shows bound ATP and the sulfate
molecule described above (Figure 18C and D). The sulfate molecules could be coming
from MgSO4 used in the crystallization experiment. However, we cannot rule out the
possibility that this anion is phosphate results from spontaneous hydrolysis of ATP γphosphate, which is known to happen in PL kinase.12 The PLP phosphate moiety or the
sulfate molecule lies adjacent to the ATP γ-phosphate, and are stabilized by a P-loop,
consisting of an anion hole formed by the highly conserved sequence motif GTGA
(residues 231–234) and the N-terminus of the helix formed by the residues 234–248. The
PLP phosphate or the sulfate molecule makes extensive hydrogen-bond interactions with
the backbone nitrogen atoms of the anion hole residues, while the rest of the PLP molecule
is located inside the active site with very limited protein contacts, consistent with a weaker
PLP ring density. The ATP γ-phosphate is further stabilized by a bound Na+, while the βphosphate is stabilized by the P-loop and Mg2+.
Comparisons of the D235A, D235N and the wild-type structures show similar folds
with root mean square deviations of ~0.2 Å. The ATP and PL binding site geometries, as
well as their associated interactions with the protein are also conserved (Figure 18 E). In
the D235N mutant, the side-chain of Asn235 occupies the same position as the wild-type
Asp235 side chain and makes a conserved hydrogen-bond interaction with the C5′-OH
group of a modeled PL.
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Figure 18: Crystal Structure of PL kinase mutants. (A) A Fo–Fc map (contoured at 2.6σ level) of
the D235A model calculated before Na+, Mg2+, PLP, PL, ATP and Ala235 side-chain were added to
the subunit B active site. (B) A 2Fo–Fc map (0.8σ level) of the subunit B active site of the D235A
model. (C) A Fo–Fc map (2.6σ level) of the D235N model calculated before Na+, Mg2+, sulfate, and
Asn235 side-chain were added to the subunit B active site. (D) A 2Fo–Fc map (0.8σ level) of the
subunit B active site of the D235N model. All maps are superimposed with the final refined models.
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In the D235A mutant, there is a non-conserved water molecule close to the Asp235
carboxylate oxygen atom (Figure 18 E). The water is close to the amide nitrogen of Gly20
(~3 Å), as well as the C5′-OH group of PL (~3 Å). The bound PL makes conserved PL
kinase interactions with the residues Ser12, Thr47, Val19 and Tyr84.

Figure 18: Crystal Structure of PL kinase mutants. (E) Stereo view comparison of the active site

of the wild-type structure in complex with ATP (grey), D235N in complex with ATP and
sulfate (cyan), and D235A in complex with PLP, PL, ATP and the non-conserved water
(magenta). Residue 235 is labeled as X235. Also shown are the cation positions.
The study unexpectedly showed less than the anticipated drop in D235A mutant
catalytic activity consistent with removal of an essential catalytic base. Since the human
PL kinase enzyme was purified with a His-tag affinity column, significant contamination
by wild-type enzyme is ruled out. Most likely, the observed activity of the D235A mutant
could be attributed to the non-conserved water molecule described above acting as a weak
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base. As reported before the ATP γ-phosphate is known to hydrolyze spontaneously,12
which suggests that even a weak catalytic base could initiate the phosphorylation reaction.
Also, unexpectedly, we observe significant activity of the D235N mutant. It is not
clear why this mutant is active, and we speculate that there could be another water
molecule in the active site of this mutant which is acting as a base. However, the crystal
structure did not identify such a water molecule, and it’s possible this water molecule
appears when the enzyme is in its pre-catalytic stage, which is not captured by the current
structure.
This study suggests that Asp235 could be the catalytic base involved in PL kinase
activity as depicted in Figure 17. In this mechanism, Asp235 forms strong hydrogen -bond
with the 5′-OH of PL to enhance the nucleophilicity of the substrate. A subsequent
nucleophilic attack by PL on the ATP γ-phosphate results in the transfer of the proton from
the 5′-OH group to the Asp235 carboxyl group, and concomitant transfer of the γphosphate to PL. However, we cannot discount the fact that a water molecule at the active
site could also be acting as a base. Most likely, the former may only be unique in the
D235N mutant, where during the pre-catalytic state, the side chain of residue Asp235
makes a hydrogen-bond interaction with the “catalytic water” to increase its basic
properties which subsequently makes nucleophilic attack on 5′-OH group of PL and
deprotonates the substrate. Resultant, negatively charged O5′ atom of PL then makes a
direct nucleophillic attack on the ATP γ-phosphate and complete the phosphorylation
reaction with transfer of the γ-phosphate of ATP to PL (Figure 19).
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Figure 19: Alternate water mediated catalytic mechanism of PL kinase.

The reduced rate of PL phosphorylation by the D235A mutant might have led to
the trapping of ATP, PL and PLP at the active site. The ability to trap a PLP in the
presence of the MgATP substrate suggests that PL kinase might use this mechanism to
self-regulate its activity. This is consistent with our kinetic study with E. coli PL kinase
that showed severe MgATP inhibition of the enzyme in the presence of PLP.8 We
speculate that this inhibition is due to formation of a non-productive PL kinase·PLP·ATP
complex.
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3.4 Conclusion
Our kinetic studies document the catalytic role of Asp235 in PL kinase activity and
suggest that Asp235 could act as the active site base to deprotonate pyridoxal prior to
phosphorylation. The crystal structure of D235A shows bound ATP, PL and PLP, while
D235N shows bound ATP and sulfate.103 Other studies such as isotope studies are needed
to reach definite conclusion about whether Asp235 is indeed acting as direct base for the
phosphorylation reaction. The observation that the active site of PL kinase can
accommodate both ATP and PLP suggests that formation of a ternary Enz•PLP•ATP
complex could occur in the wild-type enzyme, consistent with severe MgATP substrate
inhibition of PL kinase in the presence of PLP.
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CHAPTER 4
Determine the Method of Kinetic Regulation of PL Kinase

4.1 Introduction:

The crystal structures of PL kinase from several species,

including E. coli, human and sheep PL kinases have been reported. The protein is a
homodimer with an active site on each monomer composed of residues exclusively from
each respective subunit. The active site starts as a shallow groove where ATP binds, and
then stretches deeper into the protein where PL or PM or PN binds opposite but facing the
γ-phosphate of the ATP. The residues that make interactions with both substrates are
highly conserved among the PL kinase enzymes. The three ATP phosphate groups are
stabilized by an anion hole formed by the highly conserved sequence motif GTGA and the
N-terminus of a nearby helix, as well as by bound Mg2+ and K+ or Na+ respectively.7-8, 11-12
In most published PL kinase structures, the PL binding site is located about 6-7Å
from the ATP, prompting the suggestion that the protein must undergo conformational
change to a transition state that places the phosphate and the substrate closer together to
allow for transfer of the γ-phosphate from ATP to the substrate.7,
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11-12

Consistently, a

ternary sheep PL kinase-ADP-PLP complex structure shows such a conformational
change, and it’s believed to represent the catalytic conformer.11
Disruption of the B6 salvage pathway due to pathogenic mutations in PNP oxidase
or PL kinase or inhibition of these two enzymes or lack of nutritional intake of vitamin B6
is known to result in PLP deficiency, which has been implicated in several pathologies. On
the other hand, intake of too much vitamin B6 is known to result in toxic effects, including
sensory and motor neuropathies. This is due in part to the PLP aldehyde propensity to react
with several nucleophiles including non-B6 enzyme in the cell.46, 48-50 Maintaining a low
level of PLP in vivo (~1 uM) through hydrolysis of free PLP to PL by phosphatases is one
of the ways the cell has solved this problem. Consistently, the kcat values of phosphatases
are 30-fold higher than that of PL kinase.6 A second suggested mechanism, but not well
documented, is through PL kinase and/or PNP oxidase regulation. A recent study with ePL
kinase showed severe induced MgATP substrate inhibition of the enzyme in the presence
of its product, PNP or PLP. It was suggested that some control mechanism is operating for
PL kinase reaction.8 Kinetic and structural studies of hPL kinase with its substrates and
products were performed to gain insight into the regulation of PLP by PL kinase.

4.2 Methods
4.2.1 MgATP substrate inhibition studies: Human PL kinase was expressed and
purified as described earlier in chapter 3, section 3.2.1. The enzyme was dialyzed
overnight against 20 mM sodium BES buffer, pH 7.2. Kinetic assays were performed at
37 °C in a 1 cm thermostated cuvette. Initial velocity studies for the conversion of PL to
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PLP were followed at 388 nm in an Agilant 8454 spectrophotometer in 20 mM sodium
BES buffer, pH 7.2.9, 92 MgATP substrate inhibition studies of hPL kinase (285 µM) were
carried out at a fixed concentration of substrate PL (150 µM) and variable concentration of
ATP from 60 to 300 µM and three different fixed PLP concentrations of 100, 150 and 250
µM.
4.2.2 ADP product inhibition studies: Kinetic constants and mode of inhibition
for ADP were also determined at three different ADP concentration of 200, 400 and 800
µM at a saturating PL concentration of 1 mM and varied MgATP concentrations between
200 µM and 1200 µM.
4.2.3 Crystallization, data Collection and structure determination: A complex
mixture of hPL kinase (36 mg/ml enzyme in 20 mM Sodium BES buffer, pH 7.2,
containing 150 mM NaCl and 5 mM BME) and 2.5 mM each of MgATP and PLP were
incubated on ice for about 3–4 h. The complex was crystallized using precipitant
composed of 100 mM Tris-HCl, pH 8.0, 52% MPD and 2.5 mM MgSO4. For data
collection, crystals were first cryoprotected in solution containing 100 mM Tris-HCl
buffer (pH 8.0) and 50% MPD with 2.5 mM PLP and MgATP. X-ray data were collected
at 100 K using a Molecular Structure Corporation (MSC) X-Stream Cryogenic Crystal
Cooler System and an R-Axis IV++ image plate detector, a Rigaku MicroMax–007 X-ray
source equipped with MSC Varimax confocal optics operating at 40 kV and 20 mA.
The isomorphous hPL kinase structure (PDB code 2YXT)9, omitting bound
phosphate, water and MPD molecules was used as the starting model for the refinement
using the CNS program.96 After rigid body refinement, and subsequent conjugate gradient
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minimization and simulated annealing, difference density consistent with ATP, Mg+2 and
Na+ were observed at both active site. In addition, difference density consistent with a
mixture of bound PLP and MPD was also identified at the PL binding site at both active
site. These molecules and ligands were added to the models, and the structure
subsequently refined with alternate cycles of conjugate gradient minimization, simulated
annealing and B-factor refinements with intermittent model rebuilding with TOM and
COOT.111, 112
Addition of water, MPD and sulfate molecules led to the final crystallographic
Rwork/Rfree of 20.9%/25.6%. COOT was used for structure validation. Structure
solution/refinement statistics are shown in Table 5. Atomic coordinates and structure
factors for the structure of hPL kinase in complex with ATP and PLP have been deposited
in the RCSB Protein Data Bank with accession code 3KEU.
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Table 5: Refinement parameters for the human PL kinase structure with bound
ATP and PLP
Data collection statistics
Space Group
Cell Dimensions (Å)
Resolution (Å)a
No. of measurements
Unique reflections
I/sigma I
Completeness (%)
Rmerge (%)b
Structure refinement
Resolution limit (Å)
No. of reflections
Rwork (%)c
Rfree (%)d
Rmsd standard Geometry
Bond-lengths (Å)
Bond-angles (°)
Dihedral angles
Most favored regions
Additional allowed regions
Bfactors
All atoms
Protein alone
ATP
PLP
Metal ions
Sulfate
Water
MPD
a

I222
91.20, 114.58, 169.41
26.98 – 2.00 (2.07-2.00)
184435
59477 (5949)
13.3 (3.4)
98.9 (99.0)
4.9 (30.0)

26.98 – 2.10 (2.18-2.10)
51485 (4801)
20.9 (40.3)
25.6 (44.5)
0.010
1.60
91.1
8.9
43.52
42.40
37.20
69.30
43.11
62.56
51.55
66.31

Numbers in parentheses refer to the outer (highest) resolution shell.

b

Rmerge = ∑|I -〈 I〉 | /∑(I), where I is the observed intensity and 〈 I〉 is the weighted
mean of the reflection intensity.
c
Rwork = ∑||Fo| -Fc|| / ∑|Fo|, where Fo and Fc are the observed and calculated structure factor
amplitudes, respectively.
d
Rfree is the crystallographic Rwork calculated with 5 % of the data that were excluded from
the structure refinement.
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4.3 Results and discussion
4.3.1 Severe MgATP substrate inhibition of PL kinase in the presence of PLP
and evidence of tight PLP binding in PL Kinase: In our previously published study
with ePL kinase, we observed severe substrate inhibition by MgATP in the presence of
PLP or PNP, suggesting some possible control mechanism is operating for products of the
kinase reaction.8 At 200 µM ATP there is a 60% inhibition of activity. The cellular
concentration of ATP is estimated to be near 400 µM in cells, suggesting that this level of
ATP would result in almost total inhibition of the kinase activity in the presence of 250 uM
PLP. We have repeated this experiment with hPL kinase using PLP (100-250 µM). Figure
20 shows inhibition pattern of hPL kinase with PLP as a product inhibitor at a fixed
concentration of substrate PL and variable concentration of MgATP.
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Figure 20: MgATP substrate inhibition of human PL kinase in the presence of PLP
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As previously observed in the study with ePL kinase, the sharp upward
curvature in the above double reciprocal plot in the presence of PLP is most likely the
result of MgATP substrate inhibition, and at 150 µM of ATP, we observe 50% inhibition.8
This inhibition mechanism could be a physiological regulatory process utilized by PL
kinase to keep the level of PLP low in the cell as a free molecule. Intracellular
concentrations of enzymatic reactions products are maintained at certain level and one way
the cell regulates the activity of enzymes is feedback inhibition that shut down the
biochemical pathway to avoid excess product concentration. Native gradient gel analysis
rules out protein oligomerization as a possible reason for the observed inhibition.
Interestingly, the PLP in the PL kinase/MgATP complex was found to be tightly
bound as dialyzing the ternary complex overnight in the presence of MgATP, and then
running it down a 15 cm column of BioGel P6-DG equilibrated with a buffer containing
Na-BES and MgATP did not remove the bound PLP. Also of note is that the tightly bound
PLP in the PL kinase/MgATP complex is released in the presence of a PLP-dependent
enzyme, apo-SHMT (serine hydroxymethyltransferase) to activate the enzyme into its
holo-form. We hypothesize the source of this inhibition to be due to formation of a nonproductive ternary PL kinase complex of ATP and PLP (PL kinase•PLP•ATP), and that
both PLP and ATP bind at the active site. Analysis of previous ligand complex structures
of PL kinase suggests that this ternary complex could form since the 5’-OH of PL is
located 6-7 Å from the γ-phosphate of ATP, the space sufficient enough to allow
coexistence of the C5’ phosphate ester of PLP with the γ-phosphate of ATP (Figure 21). In
support of this supposition is the fact that our recently published PL kinase D235A mutant
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structure shows ATP and PLP trapped at the active site.16 If this hypothesis is proven
correct, it will be a unique case because in most feedback inhibition, the enzymatic product
confers its inhibitory activity by binding to a non-catalytic or allosteric site. For example,
L-threonine deaminase is involved in catalytic conversion of L-threonine to L-isoleucine,
and the enzyme is strongly inhibited by L-isoleucine at an allosteric site.113 Also, aspartate
kinase which catalyzes the phosphorylation of the amino acid aspartate which is a first step
in the biosynthesis of methionine into threonine and lysine, is also inhibited by its product
at an allosteric site.114

ATP

PL
ATP analog

Figure 21: Superposition of the ATP and PL bound complex of ePL kinase (colored yellow)

and the ternary ATP analog/PM crystal structure of sheep kinase (colored red). PL-bound
ePL kinase crystal structure and MgATP-bound ePL kinase crystal structure were
superimposed on each other to obtain ATP and PL bound complex of ePL kinase.
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4.3.2 ADP product inhibition of PL kinase: Above, we show that the substrate
MgATP of the kinase can inhibit the enzyme in the presence of its product, PLP. To find
out whether the enzymatic product, ADP could also inhibit the PL kinase activity, we
performed experiments to determine the Ki of ADP at fixed saturating concentration of PL
and varied concentration of ATP. Note that ADP binds at the same place as the substrate
ATP. Kinetic studies were carried out at three different ADP concentration of 200, 400
and 800 µM at a saturating PL concentration of 1 mM and varied MgATP concentrations
between 200 µM and 1200 µM. Data showed ADP competitively inhibited ATP with Ki of
361 µM (Figure 22).
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Figure 22: Determination of binding constants for ADP

4.3.3 MgATP and PLP bind to PL kinase to form a ternary complex: To test
our hypothesis that the observed hPL kinase inhibition by MgATP in the presence of PLP
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is due to the formation of a non-productive ternary complex of PL kinase•PLP•MgATP,
we co-crystallized hPL kinase with PLP and MgATP. The structure was refined to 2.1 Å,
using an already published isomorphous hPL kinase structure (PDB code 2YXT).9 The
root mean square deviation between the two protein dimers is ~0.25Å, indicating similar
overall conformation. The complex structure showed both ATP and PLP bound in both
subunit active sites (Figure 23, 24). The PLP occupies the PL binding site. We also
observe a bound MPD in later refinement cycles overlapping the bound PLP pyridine ring.
The PLP and MPD were refined using 50% occupancy for each molecule.

ATP
PLP

PLP
ATP

Figure 23: The dimeric structure, of human PL kinase with bound ATP (green), PLP (magenta),
Na+ (blue sphere), and Mg2+ (orange sphere). MPD molecule at both the active site is not shown for
clarity. Monomers A and B are colored red and yellow, respectively.
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A

ATP

PLP

B

ATP

Na
Mg+2

Mg+2

PLP

MPD

Figure 24: Crystal Structure of human PL kinase with ATP and PLP and MPD (A) A Fo–Fc map
(contoured at 2.6σ level) calculated before PLP was added to the subunit B active site. (B) A 2Fo–
Fc map (0.8σ level) of the subunit B active site. All maps are superimposed with the final refined
models.

59

As previously observed, binding of ATP in the ternary complex is stabilized by a Ploop consisting of an anion hole formed by the highly conserved sequence motif GTGA
(residues 231-234) and the N-terminus of the helix formed by the residues 234-248.9,103
The ATP binding is also stabilized Mg+2 and Na+ close to the phosphates of the ATP.
Other interactions between the ATP and the protein are all conserved. 9,103 The PLP binds
at the PL site, where the pyridine moiety makes conserved interactions with the residues
Ser12, Thr47 and Tyr84. However, these interactions are weaker compared to PL
interactions due to the fact that the pyridine moiety of PLP is displaced about ~2 Å from
the PL ring position. Interestingly, overlapping the pyridine moiety was an MPD molecule.
The PLP phosphate ester extends toward the ATP phosphate to lie adjacent to the
ATP γ-phosphate. Most significantly, we observe a second Mg+2 making interactions to
both the PLP phosphate and the ATP γ-phosphate moieties, as well as to Asp235 that
should stabilize the two phosphate positions. In addition, extensive hydrogen-bond
interactions from the P-loop to the phosphates of ATP and PLP are also essential for
stabilization of the two ligands (Figure 25).
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ATP
Na+
Mg+2

Anion hole

Mg+2
PLP

S12
Y84
T47

Figure 25: Crystal Structure of Human PL kinase in complex with bound ATP and PLP: Active

site of the wild-type structure in complex with PLP, ATP. Also shown are the cation
positions.

4.4. Conclusion
Accumulation of the PLP in the cell as a free molecule must be kept low
since it can rapidly react with amines, proteins, and thiols to form adducts.44-50 The cell has
evolved mechanisms for regulating PLP synthesis and we hypothesize that one of these
mechanisms involve PL kinase. Our studies suggest that PL kinase could be using its
substrate and/or enzymatic product to self-regulate its activity.16 Kinetic and structural
studies

strongly

point

to

a

formation
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of

non-productive

ternary

complex

(Enzyme•PLP•MgATP) as the basis of the kinase activity inhibition. Further studies are
needed to conclusively prove such an inhibitory mechanism. Our studies also show that
ADP is a competitive inhibitor of the enzyme with a Ki of 361 µM.
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CHAPTER 5
Identify Drugs and Other Compounds that are
Inhibitors of PL Kinase

5.1 Introduction: Some drugs inhibit the activity of PL kinase, which result in
disruption of B6 metabolism and PLP deficiency with concomitant neurotoxic adverse
effects such as sleeplessness, headache, restlessness, agitation, tremors and hallucinations.
Examples of these drugs are isoniazid, theophylline, progabide, cycloserine, L-DOPA,
penicillamine, and steroid contraceptives.53-61 We hypothesize that other drugs and natural
products that cause similar side effects as theophylline and other PL kinase inhibitors could
also be depleting PLP in the cell by inhibiting PL kinase activity. Kinetic and structural
studies of hPL kinase in the presence of several potential PL kinase inhibitors were
performed.

5.2 Methods
5.2.1 Selection of compounds for inhibition study: Theophylline is a
bronchodilator and its use has been associated with neurotoxic side effect due to its
inhibitory effect against PL kinase that leads to vitamin B6 deficiency. Interestingly,
enprofylline, theobromine and caffeine (Figure 26), structural analogs of theophylline also
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exhibit similar neurotoxic effects as theophylline. Although, there is no evidence or prior
studies to suggest that PL kinase inhibition is the cause of their neurotoxic side effects, we
decided to study their inhibitory activity against the enzyme due to their structural
similarities with theophylline.54-58 We also decided to study the inhibitory activities of
other drugs on PL kinase, including epinephrine, lamotrigine, metaraminol, and
mesalamine (Figure 23).

These drugs also exhibit similar neurotoxic effects as

theophylline, and most importantly they have similar structural characteristics as the
natural substrate, PL or the theophylline.62,

55

They were identified from the DrugBank

Chemical Compound database using PL or theophylline as search queries.
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Figure 26 : Selected neurotoxic drugs for inhibition studies

5.2.2 Determination of inhibition constants: Human PL kinase was expressed
and purified as described earlier in Chapter 3, section 3.2.1. Fractions containing 95%
purity, as judged by SDS-Page, were pooled and the protein solution was concentrated by
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precipitation with 60% ammonium sulfate. Human PL kinase used in the kinetic
experiments was dissolved and dialyzed overnight against 20 mM sodium BES buffer, pH
7.2. All assays were performed at 37ºC in a 1-cm thermostated cuvette. Initial velocity
studies for the conversion of PL to PLP were followed at 388nm in an Agilant 8454
spectrophotometer in 20 mM sodium BES buffer, pH 7.2.9, 92 As a first step, percentage
inhibition of hPL kinase with each tested drug (100 µM) was measured at a saturating
MgATP concentration of 1 mM and fixed PL concentration of 75 uM. Detailed kinetic
studies to determine Ki and mode of inhibition for the drugs showing more than 30%
inhibition were carried out at three different drug concentrations of 50, 100 and 150 µM
under two experimental conditions: at a saturating MgATP concentrations of 1 mM and
varied PL concentrations between 20 and 100 µM, and reciprocally at a saturating PL
concentrations of 500 µM and varied MgATP concentrations between 150 and 800 µM.
Inhibition constants were determined by double reciprocal plots.
5.2.3 Crystallization, data Collection, and structure refinement: Human PL
kinase protein was dialyzed overnight against 20 mM Sodium BES buffer, pH 7.2,
containing 150 mM NaCl and 5 mM BME, and then concentrated to 36mg/ml (1 mM).
Crystallization of hPL kinase in the presence of 2.5 mM theophylline/ or caffeine/ or
enprofylline/ or lamotrigine was attempted at room temperature using the hanging-drop
vapor diffusion technique. The complex mixtures were first incubated on ice for about 1-2
hr before screening for crystallization.
Crystallization drops were composed of 2.5 µL of protein solution (with 2.5 mM
drug) and 2.5 µL of reservoir and equilibrated against 700 µL reservoir solution (100 mM
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Tris-HCl, pH 8.0, and 52% MPD, 2.5 mM MgSO4). X-ray quality crystals were obtained
for only the protein-theophylline complex. For data collection, crystals were cryoprotected
in solution containing 100 mM Tris-HCl buffer (pH 8.0), 2.5 mM theophylline and 50%
MPD before flash cooling in a cryogenic nitrogen gas stream. X-ray data were collected at
100 K using a Molecular Structure Corporation (MSC) X-Stream Cryogenic Crystal
Cooler System and an R-Axis IV++ image plate detector, a Rigaku MicroMax–007 X-ray
source equipped with MSC Varimax confocal optics operating at 40 kV and 20 mA.
The isomorphous hPL kinase wild type structure (PDB code 2YXT), 9 and omitting
bound phosphate, water and MPD molecules was used as the starting model for the
refinements of the theophylline bound structure. All refinements were performed with the
CNS program.96 A statistically random selection of 5 % of the total reflection data was
excluded from the refinement and used to calculate the Rfree as a monitor of model bias.
After rigid body refinement, and subsequent conjugate gradient minimization, simulated
annealing and B-factor refinements, theophylline density was identified at the PL binding
site in the A subunit. However, the B subunit active site was found to be occupied by an
MPD molecule. Densities were also identified for Na+ in both subunit active sites.
These molecules and ligands were added to the model, and the ensuing model
subsequently refined with alternate cycles of conjugate gradient minimization, simulated
annealing and B-factor refinements with intermittent model rebuilding with TOM and
COOT.111,

112

Addition of 337 water, 12 MPD and 7 sulfate molecules led to the final

crystallographic Rwork/Rfree of 20.2%/25.5%. COOT was used for structure validation. The
structure solution/refinement statistics are shown in Table 6. Atomic coordinates and
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structure factors for the structure of hPL kinase in complex with theophylline have been
deposited in the RCSB Protein Data Bank with accession code 3KBI.
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Table 6: Refinement parameters for the human PL kinase structure with bound
theophylline
Data collection statistics
Space Group
Cell Dimensions (Å)
Resolution (Å)a
No. of measurements
Unique reflections
I/sigma I
Completeness (%)
Rmerge (%)b
Structure refinement
Resolution limit (Å)
No. of reflections
Rwork (%)
Rfree (%)c
Rmsd standard Geometry
Bond-lengths (Å)
Bond-angles (°)
Dihedral angles
Most favored regions
Additional allowed regions
Bfactors
All atoms
Protein alone
Theophylline
Metal ions
Sulfate
Water
MPD
a

I222
92.30, 115.85, 171.90
37.68 – 2.10 (2.18-2.10)
157598
52989 (5317)
18.5 (4.1)
98.1 (98.0)
3.2 (24.1)

29.19 – 2.10 (2.18-2.10)
52986 (4941)
20.4 (33.5)
25.5 (37.2)
0.007
1.30
91.6
8.4
48.15
46.79
85.78
95.42
66.13
55.94
75.83

Numbers in parentheses refer to the outer (highest) resolution shell.

b

Rmerge = ∑|I -〈 I〉 | /∑(I), where I is the observed intensity and 〈 I〉 is the weighted
mean of the reflection intensity.
c
Rwork = ∑||Fo| -Fc|| / ∑|Fo|, where Fo and Fc are the observed and calculated structure factor
amplitudes, respectively.
d
Rfree is the crystallographic Rwork calculated with 5 % of the data that were excluded from
68

the structure refinement.
5.3 Results and Discussion
5.3.1 Inhibition studies: Initial inhibition studies revealed some of the tested
drugs (Figure 26) as hPL kinase inhibitors, with theophylline being the most potent (Table
7). Subsequently, detailed kinetic studies of the drugs showing more than 30% inhibition
were carried out to determine Ki and mode of inhibition. Double reciprocal plots of
reaction velocities against PL or MgATP concentrations in the presence and absence of
theophylline show a mixed competitive inhibition profile with Ki values of 71 µM and 225
µM, respectively (Figure 27). This result suggests theophylline could be binding to
substrate PL site, and the mixed competitive behavior is likely due to the fact that binding
of PL and ATP are synergistic. It is also quite possible that theophylline could be binding
at both PL and ATP site, as we have previously observed for MPD molecules.9 Previous
studies with theophylline using non-purified PL kinase enzyme based on HPLC separation
and fluorometric detection of PL and PLP also reached similar conclusions.55
Enprofylline, theobromine and caffeine are structural analogs of theophylline
(Figure 26), and the first two compounds, like theophylline, are bronchodilators and had
been used for treating asthma.56 Enprofylline, caffeine and theobromine also showed
inhibitory actions against hPL kinase, resulting in 33%, 22% and 21% inhibition at 100
µM, respectively. Detailed inhibition studies of human PL kinase with enprofylline
revealed mixed competitive inhibition with Ki of 228 µM. Lamotrigine, also showed
mixed competitive inhibition profile with Ki of 160 µM and this result correlates well with
other studies that reported a drop in serum concentration of PLP of epileptic patients when
treated with anticonvulsants, such as lamotrigine.62 We did not observe any significant
hPL kinase inhibition with the drugs, epinephrine, mesalamine, and metaraminol.
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Table 7: Kinetic parameters of human PL Kinase inhibition by drugs

Compound

% Inhibitiona

Ki (uM)b

Inhibition Mechanism b

Theophylline

60

71

Mixed

Theobromine

21

ND

ND

Caffiene

22

ND

ND

Enprofylline

33

228

Mixed

Epinephrine

Null

ND

ND

Metaraminol

Null

ND

ND

Mesalamine

Null

ND

ND

Lamotrigine

45

160

Mixed

a

PL, ATP and drug concentrations of 75 uM, 1 mM and 100 uM, respectively.

b

At variable PL and saturated ATP. dND (not determined yet).
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Figure 27: Determination of binding mode and inhibition constants of Theophylline

5.3.2 Structure of PL kinase-Inhibitor Complex Our inhibition studies suggest
that theophylline and the other compounds could be binding to the active site of PL kinase,
and inhibiting the enzyme. We therefore undertook structural studies to determine the
precise binding modes of these compounds. Human PL kinase was co-crystallized with
theophylline and refined to 2.1 Å, using the isomorphous hPL kinase structure (PDB code
2YXT).9 Other compounds, including caffeine, enprofylline and lamotrigine were also cocrystallized with hPL kinase, but we were unable to obtain X-ray quality crystals. The
crystal structure showed bound theophylline at the PL binding site (Figure 28, 29). Even
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though we observe mixed inhibition, there was no obvious binding of theophylline at the
ATP site, which could be due to weak binding.

MPD

Na
Na
Theophylline

Figure 28: The dimeric structure, of human PL kinase with bound Thephylline, MPD, Na+ (brown
sphere). Monomers A and B are colored red and yellow, respectively.

A hydrogen-bond interaction is formed between N7 of theophylline and the
hydroxyl group of Ser12 side-chain. The N7 and N9of theophylline are also involved in
hydrogen bond interactions with nearby water molecules. These water molecules make
interactions with the main-chain nitrogen atom of residue Ser12, and the anion hole
residue Gly231. The anion hole is formed by the highly conserved sequence motif GTGA
(residues 231-234) that stabilizes bound ATP.9 There are also hydrogen-bond interactions
between O10 and O12 of theophylline with the hydroxyl group of Ser12 and Thr47,
respectively. The O12 atom also makes hydrogen-bond interaction with main-chain
nitrogen atom of Thr47. Theophylline also makes an apparent π- π interaction with Tyr84.
Other hydrophobic interactions are made to Val19 and Val231. These hydrogen-bond and
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hydrophobic interactions are also observed with PL binding. We observed theophylline
density in only A subunit. Also, of note is that Roscovitine, a PL kinase inhibitor, is also
known to bind at the same position as theophylline and makes similar protein
interactions.70-71 Roscovitine has strikingly similar core structural features as theophylline
(Figure 29, 30 ).

S12
W

T47
Theophylline
W
G231

Figure 29: Interactions between theophylline, human PL kinase active site residues serine
12(S12), threonine 47 (T47), glycine 231 (G231), and water (W). Hydrogen-bond interactions are
denoted with dotted lines.
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A

S12

T47
Theophylline
G231

B

S12
W

T47
W Theophylline
G231

Figure 30 : Crystal Structure of human PL kinase with theophylline and active site residues
serine 12(S12), threonine 47 (T47), glycine 231 (G231), and water (W). A: A Fo–Fc map
(contoured at 2.7σ level) calculated before theophylline was added to the subunit A active site.
B: A 2Fo–Fc map (0.8σ level) of the subunit A active site. All maps are superimposed with the
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final refined models.

In the absence of crystal structures for the structural analogs of theophylline, we
decided to visually model these compounds based on theophylline binding mode to gain
insight into the structural basis of the differences in their inhibitory activities. The
significantly lower affinity of caffeine and theobromine seems to be due to the imidazole
nitrogen, N7 being methylated and not available to make hydrogen-bond interactions with
the nearby Ser12 hydroxyl group and water molecule as observed in theophylline.
Although, not obvious it seems that the reduced affinity of enprofylline compared to
theophylline could be due to steric crowding by the enprofylline propyl moiety (Figure
31).

S12

W

W

T47

G231

Figure 31: Binding modes of caffeine (red), theobromine (yellow), enprofylline (orange),
and theophylline (green) at the active site of hPL kinase. Active site residues serine
12(S12), threonine 47 (T47), glycine 231 (G231), and Water (W) are shown. Hydrogenbond interactions are denoted with dotted lines.
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5.4 Conclusion
Many studies have reported several drugs, as well as natural compounds, that
inhibit PL kinase activity resulting in PLP deficiency with concomitant neurotoxic
effects.53-61 We tested 8 drugs identified as potential PL kinase inhibitors based on their
neurotoxic properties and similar structural features as PL or theophylline. Out of the 8
compounds, 5 showed significant inhibitory activities against PL kinase, while three did
not. Lamotrigine, theophylline and its structural analogs, including enprofylline,
theobromine and caffeine inhibited hPL kinase. Structural studies also confirm the results
of the kinetic studies which suggest that theophylline bind at the PL binding site resulting
in PL kinase inhibition. The result of this study suggests that neurotoxic effects of some
drugs could be due to their inhibitory activity against PL kinase by disrupting the binding
of the B6 substrate. More studies, including cell-based and possibly in-vivo with some of
these inhibitors are planned to determine the effect of these compounds on vitamin B6
pool.
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